The Cell Morphology Core is an independent service facility that provides a full range of services for morphologically based studies ranging from electron microscopy to complex image analysis. Services include preparation of tissues for microscopic analysis including paraffin embedding and sectioning, and cryosectioning. The Core also provides services for detection of transgenes and transgene products including in situ hybridization and immunohistochemistry. This core has a track record of interaction with the investigators on Projects 1, 2 and 6, and for the proposed PEGT, will also support studies outlined in Projects 3 and 4. This core has a track record of interaction with the investigators on Projects 1, 2 and 6, and for the proposed PEGT, will also support studies outlined in Projects 3 and 4. The core's major assets include its first-rate equipment and an interactive and knowledgeable staff. The core is structured so that core personnel can provide services on a fee-for-service basis, or if they prefer investigators an use the core's facilities to perform the studies themselves, with advice and assistance provided as needed by core staff. Because of the organizational structure already in place, this core is well-qualified to serve as a shared resource for all the PEGTs and for other NHLBI-funded investigators.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL066948-03
Application #
6664075
Study Section
Special Emphasis Panel (ZHL1)
Project Start
2002-09-01
Project End
2003-08-31
Budget Start
Budget End
Support Year
3
Fiscal Year
2002
Total Cost
$248,650
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Margaritis, Paris (2010) Long-term expression of canine FVIIa in hemophilic dogs. Thromb Res 125 Suppl 1:S60-2
Margaritis, Paris; Roy, Elise; Aljamali, Majed N et al. (2009) Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood 113:3682-9
Bedi, Maninder S; Alvarez Jr, Rene J; Kubota, Toru et al. (2008) Myocardial Fas and cytokine expression in end-stage heart failure: impact of LVAD support. Clin Transl Sci 1:245-8
Aljamali, Majed N; Margaritis, Paris; Schlachterman, Alexander et al. (2008) Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality. J Clin Invest 118:1825-34
Akache, Bassel; Grimm, Dirk; Shen, Xuan et al. (2007) A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Mol Ther 15:330-9
Chen, Jian; Wu, Qi; Yang, Pingar et al. (2006) Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy. Mol Ther 13:260-9
Bedi, Maninder; McNamara, Dennis; London, Barry et al. (2006) Genetic susceptibility to atrial fibrillation in patients with congestive heart failure. Heart Rhythm 3:808-12
Grimm, Dirk; Pandey, Kusum; Nakai, Hiroyuki et al. (2006) Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J Virol 80:426-39
Inagaki, Katsuya; Fuess, Sally; Storm, Theresa A et al. (2006) Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 14:45-53
Manno, Catherine S; Arruda, Valder R; Pierce, Glenn F et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12:342-7

Showing the most recent 10 out of 36 publications